Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort

Imagem de Miniatura
Arquivos
art_SILVA_Pharmacological_treatment_with_lipidlowering_agents_after_molecular_identification_2022.PDF (319.24 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER LTD
Autores
SILVA, P. R. D. S.
Citação
JOURNAL OF CLINICAL LIPIDOLOGY, v.16, n.2, p.198-207, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by the presence of high levels of total and low-density lipoprotein cholesterol (LDL-C). Statin treatment is recommended for all adults with FH. Objective: Here we have studied the main predictors of the use of lipid-lowering agents at one-year follow-up in a large cohort of FH patients. Methods: Open prospective cohort of individuals resident in São Paulo, Brazil who were enrolled in a FH cascade screening program. We used a multivariate logistic regression analysis to determine predictive variables for the non-adherence of lipid-lowering drugs. Results: A total of 1,360 HF participants were included. At the one-year follow-up (T1), the rates of lipid-lowering treatment were 92%, 76%, and 78% from the genetic positive proband (index cases, IC), genetic negative IC and genetic positive first-degree relatives, respectively. Receiving a positive genetic test for FH (OR: 4.85; CI 95%: 2.97 – 7.93, p value < 0.05), use of lipid-lowering treatment at T0 (OR: 5.01; CI 95%: 3.18 – 7.90, p value < 0.05) and age (OR: 1.04; CI 95%: 1.02 – 1.06) were independently associated with the use of a lipid-lowering drug at T1. Conclusion: Index cases with a positive genetic result increase their prevalence of lipid-lowering medication use. Positive relatives did not have the expected adherence; we could notice a significant increase in the prevalence of treatment starting after a positive genetic test. The independent predictors for lipid-lowering treatment were age, a positive genetic test and previous institution of treatment before the genetic test result. © 2022
Palavras-chave
Cascade genetic screening, Familial hypercholesterolemia, Genetics, Lipid-lowering, Prevention
URI
https://observatorio.fm.usp.br/handle/OPI/55892
Referências
  1. Bouhairie V.E., Goldberg A.C., Familial hypercholesterolemia, Cardiol Clin, 33, pp. 169-179, (2015)
  2. Silva P., Jannes C.E., Marsiglia J.D.C., Krieger J.E., Santos R.D., Pereira A.C., Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia, Atherosclerosis, 250, pp. 144-150, (2016)
  3. Mangili L.C., Miname M.H., Silva P.R.S., Et al., Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study, Atherosclerosis, 263, pp. 393-397, (2017)
  4. Raal F.J., Hovingh G.K., Catapano A.L., Familial hypercholesterolemia treatments: Guidelines and new therapies, Atherosclerosis, 277, pp. 483-492, (2018)
  5. Beheshti S.O., Madsen C.M., Varbo A., Nordestgaard B.G., Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects, J Am Coll Cardiol, 75, pp. 2553-2566, (2020)
  6. Benn M., Watts G.F., Tybjaerg-hansen A., Nordestgaard B.G., (2016)
  7. Pang J., Marais A.D., Blom D.J., Et al., Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice, Atherosclerosis, 277, pp. 470-476, (2018)
  8. Jannes C.E., Santos R.D., de Souza Silva P.R., Et al., Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects, Atherosclerosis, 238, pp. 101-107, (2015)
  9. Hagger M.S., Hardcastle S.J., Hu M., Et al., Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia, Atherosclerosis, 277, pp. 493-501, (2018)
  10. Mach F., Baigent C., Catapano A.L., Et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk, Eur Heart J, 41, pp. 111-188, (2020)
  11. Alonso R., de Isla L.P., Muniz-Grijalvo O., Mata P., Barriers to early diagnosis and treatment of familial hypercholesterolemia: Current perspectives on improving patient care, Vasc Health Risk Manag, 16, pp. 11-25, (2020)
  12. Perez de Isla L., Arroyo-Olivares R., Muniz-Grijalvo O., Et al., Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study, J Clin Lipidol, 13, pp. 989-996, (2019)
  13. Osterberg L., Blaschke T., Adherence to Medication, N Engl J Med, 353, pp. 487-497, (2005)
  14. Silva P.R.S., Jannes C.E., Oliveira T.G.M., Et al., Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil, Atherosclerosis, (2017)
  15. Galema-Boers J.M.H., Lenzen M.J., Van Domburg R.T., Et al., Predicting non-adherence in patients with familial hypercholesterolemia, Eur J Clin Pharmacol, 70, pp. 391-397, (2014)
  16. Casula M., Scotti L., Tragni E., Merlino L., Corrao G., Catapano A.L., Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia, Atherosclerosis, 254, pp. 172-178, (2016)
  17. Vohnout B., Fabryova L., Klabnik A., Et al., Treatment pattern of familial hypercholesterolemia in Slovakia: targets, treatment and obstacles in common practice, Atherosclerosis, 277, pp. 323-326, (2018)
  18. Umans-Eckenhausen M.A.W., Defesche J.C., Van Dam M.J., Kastelein J.J.P., Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia, Arch Intern Med, 163, pp. 65-68, (2003)
  19. Huijgen R., Kindt I., Verhoeven S.B.J., Et al., Two years after molecular diagnosis of familial hypercholesterolemia: Majority on cholesterol-lowering treatment but a minority reaches treatment goal, PLoS One, 5, pp. 1-7, (2010)
  20. Perez De Isla L., Alonso R., Watts G.F., Et al., Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up, J Am Coll Cardiol, 67, pp. 1278-1285, (2016)
  21. Kinnear F.J., Wainwright E., Perry R., Et al., Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: A qualitative evidence synthesis, BMJ Open, 9, (2019)
  22. Hallowell N., Jenkins N., Douglas M., Et al., A qualitative study of patients’ perceptions of the value of molecular diagnosis for familial hypercholesterolemia (FH), J Commun Genet, 8, pp. 45-52, (2017)
  23. Jenkins N., Lawton J., Douglas M., Et al., How do index patients participating in genetic screening programmes for familial hypercholesterolemia (FH) interpret their DNA results? A UK-based qualitative interview study, Patient Educ Couns, 90, pp. 372-377, (2013)
  24. do Nascimento R.C.R.M., Guerra A.A., Alvares J., Et al., Statin use in Brazil: findings and implications, Curr Med Res Opin, 34, pp. 1809-1817, (2018)
  25. Bittencourt M.S., Staniak H.L., Pereira A.C., Et al., Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), Clin Cardiol, 39, pp. 215-222, (2016)
  26. Stirratt M.J., Dunbar-Jacob J., Crane H.M., Et al., Self-report measures of medication adherence behavior: recommendations on optimal use, Transl Behav Med, 5, pp. 470-482, (2015)

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - LIM/31